home
顺序
主题
题目
日子
116
Domestic expert positively evaluates rivoceranib’s phase 3 clinical results
admin
2022.09.13
115
HLB’s anticancer drug candidate shows world’s longest survival duration against liver cancer
admin
2022.09.08
114
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression
admin
2022.09.08
113
HLB to supply ₩18.5 billion worth of sterile foam swabs to Abbott
admin
2022.09.06
112
HLB confirms rivoceranib’s safety in phase 1 gastric cancer trial
admin
2022.09.06
111
HLB, “Apply for riboceranib pre-NDA meeting with US FDA”
admin
2022.08.24
110
HLB to release phase 3 results of cancer drug candidate at ESMO 2022
admin
2022.08.24
109
Immunomic Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ITI-3000 pDNA Vaccine for the Treatment of Merkel Cell Carcinoma
admin
2022.07.25
108
HLB’s rivoceranib proven effective in esophageal cancer
admin
2022.07.21
107
Rivoceranib’s combined clinical results will be known at IASLC 2022: HLB
admin
2022.07.15